SCHEMBL28512376

SCHEMBL28512376

CCCc1c(C)ccc(C(=O)O)c1O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LDHA P00338 3/20 0.47
LDHB P07195 3/20 0.47
KDM4E B2RXH2 2/20 0.47
ALDH1A1 P00352 1/20 0.47
HPGD P15428 1/20 0.47
HSD17B10 Q99714 1/20 0.47
SELL P14151 1/20 0.42
SELP P16109 1/20 0.42
GRM2 Q14416 1/20 0.42
PPARA Q07869 2/20 0.41
MCL1 Q07820 1/20 0.41
RARB P10826 1/20 0.40
HMGB1 P09429 1/20 0.40
CXCL12 P48061 1/20 0.40
LMNA P02545 1/20 0.39
CYP1A2 P05177 1/20 0.39
MAPT P10636 1/20 0.39
CYP2C9 P11712 1/20 0.39
NFKB1 P19838 1/20 0.39
PPARG P37231 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13452821 0.86 PPARG (0.48) GRM2PPARALMNACYP1A2MAPT
SCHEMBL2581660 0.85 KDM4E (0.50) LDHAKDM4EALDH1A1HPGDHSD17B10
SCHEMBL8262764 0.84 HSP90AB1 (0.43) LDHALDHBKDM4EHSD17B10GRM2
SCHEMBL10726758 0.84 SELL (0.53) LDHALDHBKDM4EALDH1A1HPGD
SCHEMBL8226800 0.84 GABRP (0.41) LDHALDHBKDM4EALDH1A1HPGD
SCHEMBL28732290 0.82 PPARA (0.41) LDHALDHBKDM4EPPARAMCL1
SCHEMBL8321013 0.81 CTSD (0.41) LDHALDHBHSD17B10GRM2PPARA
SCHEMBL2924329 0.81 MMP2 (0.46) LDHALDHBKDM4EALDH1A1SELL
SCHEMBL6693155 0.80 PPARA (0.49) KDM4EALDH1A1HPGDHSD17B10SELL
SCHEMBL750714 0.78 CYP1A2 (0.46) LDHALDHBKDM4EPPARAMCL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106573036-B Combination therapy for ameliorating adverse side effects of chemotherapy 益生生技开发股份有限公司 2021-02-02 CN disclosed